Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:359–86.

Article  Google Scholar 

Karati D, Shaoo KK, Mahadik KR, Kumr D. Glycogen synthase kinase-3β inhibitors as a novel promising target in the treatment of cancer: medicinal chemistry perspective. Results Chem. 2022. https://doi.org/10.1016/j.rechem.2022.100532.

Article  Google Scholar 

Karati D, Mahadik KR, Trivedi P, Kumar D. Molecular insights on selective and specific inhibitors of cyclin dependent kinase 9 enzyme (CDK9) for the purpose of cancer therapy. Anticancer Agents Med Chem. 2022;22:1–20.

Google Scholar 

Karati D, Mahadik KR, Trivedi P, Kumar D. Alkylating agents, the road less traversed, changing anticancer therapy. Anticancer Agents Med Chem. 2021;21:1–7.

Google Scholar 

Karati D, Mahadik KR, Trivedi P, Kumar D. The emerging role of janus kinase inhibitors in the treatment of cancer: current cancer drug. Targets. 2022;22(3):221–33.

Google Scholar 

Godman CA, Joshi R, Tierney BR, Greenspan E, Rasmussen TP, Wang HW, Shin DG, Rosenberg DW, Giardina C. HDAC3 impacts multiple oncogenic pathways in colon cancer cells with effects on wnt and vitamin D signaling. Cancer Biol Ther. 2008;7:1570–80.

Article  Google Scholar 

Shao Y, Gao Z, Marks PA, Jiang X. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA. 2004;101:18030–5.

Article  Google Scholar 

Handy DE, Castro R, Loscalzo J. Epigenetic modifications: basic mechanisms and role in cardiovascular disease. Circulation. 2011;123:2145–56.

Article  Google Scholar 

Ganai SA. HDACs and their distinct classes. In: Ganai SA, editor. Histone deacetylase inhibitors—Epidrugs for neurological disorders. Singapore: Springer; 2019. p. 2–25.

Chapter  Google Scholar 

Zagni C, Floresta G, Monciino G, et al. The search for potent, small-molecule HDACIs in cancer treatment: a decade after vorinostat. Med Res Rev. 2017;37(6):1373–428.

Article  Google Scholar 

Falkenberg KJ, Johnstone RW. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov. 2014;13(9):673–91.

Article  Google Scholar 

Zwergel C, Stazi G, Valente S, et al. histone deacetylase inhibitors: updated studies in various epigenetic-related diseases. J Clin Epigenetics. 2016;2:1–7.

Google Scholar 

Lagger G, O’Carroll D, Rembold M, et al. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J. 2002;21(11):2672–81.

Article  Google Scholar 

Dokmanovic M, Clarke C, Marks PA. Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res. 2007;5(10):981–9.

Article  Google Scholar 

Montgomery RL, Davis CA, Potthoff MJ, et al. Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility. Genes Dev. 2007;21(14):1790–802.

Article  Google Scholar 

Marchion DC, Bicaku E, Turner JG, et al. HDAC2 regulates chromatin plasticity and enhances DNA vulnerability. Mol Cancer Ther. 2009;8(4):794–801.

Article  Google Scholar 

Bhaskara S, Chyla BJ, Amann JM, et al. Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control. Mol Cell. 2008;30(1):61–72.

Article  Google Scholar 

Marks PA. The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin Investig Drugs. 2010;19(9):1049–66.

Article  Google Scholar 

Chen B, Cepko CL. HDAC4 regulates neuronal survival in normal and diseased retinas. Science. 2009;323(5911):256–9.

Article  Google Scholar 

Williams AH, Valdez G, Moresi V, et al. MicroRNA-206 delays ALS progression and promotes regeneration of neuromuscular synapses in mice. Science. 2009;326(5959):1549–54.

Article  Google Scholar 

Chang S, Young BD, Li S, et al. Histone deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10. Cell. 2006;126(2):321–34.

Article  Google Scholar 

Haggarty SJ, Koeller KM, Wong JC, et al. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci USA. 2003;100(8):4389–94.

Article  Google Scholar 

Parmigiani RB, Xu WS, Venta-Perez G, et al. HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation. Proc Natl Acad Sci USA. 2008;105(28):9633–8.

Article  Google Scholar 

Zhang X, Yuan Z, Zhang Y, et al. HDAC6 modulates cell motility by altering the acetylation level of cortactin. Mol Cell. 2007;27(2):197–213.

Article  Google Scholar 

Kovacs JJ, Murphy PJ, Gaillard S, et al. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell. 2005;18(5):601–7.

Article  Google Scholar 

Kawaguchi Y, Kovacs JJ, McLaurin A, et al. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell. 2003;115(6):727–38.

Article  Google Scholar 

Boyault C, Gilquin B, Zhang Y, et al. HDAC6-p97/VCP controlled polyubiquitin chain turnover. EMBO J. 2006;25(14):3357–66.

Article  Google Scholar 

Villagra A, Cheng F, Wang HW, et al. The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nat Immunol. 2009;10(1):92–100.

Article  Google Scholar 

Banerjee S, Adhikari N, Amin SA, Jha T. Histone deacetylase 8 (HDAC8) and its inhibitors with selectivity to other isoforms: an overview. Eur J Med Chem. 2008. https://doi.org/10.1016/j.ejmech.2018.12.039.

Article  Google Scholar 

Chakrabarti A, Oehme I, Witt O, Oliveira G, Sippl W, Romier C, Pierce RJ, Jung M. HDAC8: a multifaceted target for therapeutic interventions trends pharmacol. Sci. 2015;36:481–92.

Google Scholar 

Autin P, Blanquart C, Fradin D. Epigenetic drugs for cancer and microRNAs: a focus on histone deacetylase inhibitors. Cancers. 2019;11:1530.

Article  Google Scholar 

Jenke R, Reßing N, Hansen FK, Aigner A, Büch T. Anticancer therapy with HDAC inhibitors: mechanism-based combination strategies and future perspectives. Cancers. 2021;13:634.

Article  Google Scholar 

Kim MS, Kwon HJ, Lee YM, Baek JH, et al. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med. 2001;7:437–43.

Article  Google Scholar 

Fajas L, Egler V, Reiter R, Hansen J, Kristiansen K, Debril MB, et al. The retinoblastoma-histone deacetylase 3 complex inhibits PPARgamma and adipocyte differentiation. Dev Cell. 2002;3:903–10.

Article  Google Scholar 

Knutson SK, Chyla BJ, Amann JM, Bhaskara S, Huppert SS, Hiebert SW. Liver-specific deletion of histone deacetylase 3 disrupts metabolic transcriptional networks. EMBO J. 2008;27:1017–28.

Article  Google Scholar 

Choi JH, Kwon HJ, Yoon BI, Kim JH, Han SU, Joo HJ, et al. Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn J Cancer Res. 2001;92:1300–4.

Article  Google Scholar 

Ashraf N, Zino S, Macintyre A, Kingsmore D, Payne AP, et al. Altered sirtuin expression is associated with node-positive breast cancer. Br J Cancer. 2006;95:1056–61.

Article  Google Scholar 

Adams H, Fritzsche FR, Dirnhofer S, Kristiansen G, Tzankov A. Class I histone deacetylases 1, 2 and 3 are highly expressed in classical Hodgkin’s lymphoma. Expert Opin Ther Targets. 2010;14:577–84.

Article  Google Scholar 

Luo J, Su F, Chen D, Shiloh A, Gu W. Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature. 2000;408:377–81.

Article  Google Scholar 

Siddiqui H, Solomon DA, Gunawardena RW, Wang Y, Knudsen ES. Histone deacetylation of RB-responsive promoters: requisite for specific gene repression but dispensable for cell cycle inhibition. Mol Cell Biol. 2003;23:7719–31.

Article  Google Scholar 

Cras A, Darsin-Bettinger D, Balitrand N, Cassinat B, Soulie A, Toubert ME, et al. Epigenetic patterns of the retinoic acid receptor beta2 promoter in retinoic acid-resistant thyroid cancer cells. Oncogene. 2007;26:4018–24.

Article  Google Scholar 

Park SY, Kim JS. A short guide to histone deacetylases including recent progress on class II enzymes. Exp Mol Med. 2020;52(2):204–12.

Article  Google Scholar 

Ganai SA. Strong involvement of classical histone deacetylases and mechanistically distinct sirtuins in bellicose cancers. In: Ganai SA, editor. histone deacetylase inhibitors in combinatorial anticancer therapy. Singapore: Springer; 2020. p. 75–95.

Chapter  Google Scholar 

Oehme I, Deubzer HE, Wegener D, Pickert D, Linke JP, Hero B, et al. Histone deacetylase 8 in neuroblastoma tumorigenesis. Clin Cancer Res. 2009;15:91–9.

Article  Google Scholar 

Vanaja GR, Ramulu HG, Kalle AM. Overexpressed HDAC8 in cervical cancer cells shows functional redundancy of tubulin deacetylation with HDAC6. Cell Commun Signal. 2018;16:20.

Article  Google Scholar 

Abbas A, Gupta S. The role of histone deacetylases in prostate cancer. Epigenetics. 2008;3(6):300–9.

Article  Google Scholar 

Deubzer HE, Schier MC, Oehme I, Lodrini M, Haendler B, Sommer A, et al. HDAC11 is a novel drug target in carcinomas. Int J Cancer. 2013;132:2200–8.

Article  Google Scholar 

Thole TM, Lodrini M, Fabian J, Wuenschel J, Pfeil S, Hielscher T, et al. Neuroblastoma cells depend on HDAC11 for mitotic cell cycle progression and survival. Cell Death Dis. 2017;8:e2635.

Article  Google Scholar 

Vannini A, Volpari C, Filocamo G, Casavola EC, Brunetti M, Renzoni D, et al. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc Natl Acad Sci USA. 2004;101:15064–9.

Article  Google Scholar 

Wu J, Du C, Lv Z, Ding C, Cheng J, Xie H, et al. The up-regulation of histone deacetylase 8 promotes proliferation and inhibits apoptosis in hepatocellular carcinoma. Dig Dis Sci. 2013;58:3545–53.

Article  Google Scholar 

Park SY, Jun JA, Jeong KJ, Heo HJ, Sohn JS, Lee HY, et al. Histone deacetylases 1, 6 and 8 are critical for invasion in breast cancer. Oncol Rep. 2011;25:1677–81.

Google Scholar 

Wickstrom SA, Masoumi KC, Khochbin S, Fassler R, Massoumi R. CYLD negatively regulates cell-cycle progression by inactivating HDAC6 and increasing the levels of acetylated tubulin. EMBO J. 2010;29:131–44.

Article  Google Scholar 

Song C, Zhu S, Wu C, Kang J. Histone deacetylase (HDAC) 10 suppresses cervical cancer metastasis through inhibition of m